Findings from Dana-Farber Cancer Institute Reveals New Findings on Mantle Cell Lymphoma (Is Rituximab Retro In Mantle Cell Lymphoma?).

The article from Dana-Farber Cancer Institute discusses new research on mantle cell lymphoma (MCL). Topics include the long-term follow-up results of the LYMA101 clinical trial, the use of obinutuzumab showing superior outcomes compared to rituximab in terms of minimal residual disease negativity, progression-free survival, and overall survival, and the implications of these findings for potential changes in frontline treatment strategies for MCL.